OBJECTIVE: Expansion of autoreactive CD4+CD28(null) T cells is associated with extraarticular disease manifestations, including rheumatoid vasculitis, and it has recently been demonstrated that expansion of these T cells is associated with anticytomegalovirus (anti-CMV) seropositivity. This study was undertaken to investigate a possible link between latent CMV infection and rheumatoid arthritis (RA). METHODS: In a retrospective analysis, anti-CMV antibodies and clinical, serologic, and radiologic parameters of joint destruction were examined in 202 RA patients and 272 healthy controls. In addition, frequencies of CD4+CD28(null) T cells; concentrations of the cytokines monocyte chemotactic protein 1 (MCP-1), interferon-α (IFNα), and IFN-inducible protein 10; and anti-CMV-specific T cell responses were analyzed in RA patients. RESULTS: Overall, no significant difference in the frequency of anti-CMV seropositivity between RA patients and healthy controls was observed. Among individuals older than age 55 years, however, anti-CMV IgG antibodies were significantly more frequent in RA patients than controls (65.3% and 54.7%, respectively; P = 0.05). Anti-CMV seropositivity in RA patients was associated with an increased frequency of CD4+CD28(null) T cells and increased serum concentrations of MCP-1. The frequency of anti-CMV-specific CD4+ T cells producing IFNγ was increased in RA patients compared to controls. Most importantly, anti-CMV-seropositive RA patients showed radiographic evidence of more advanced joint destruction and had increased frequencies of joint-related surgical procedures, indicating more severe joint disease. CONCLUSION: Our findings indicate that latent CMV infection aggravates the clinical course of RA and is associated with increased frequencies of CD4+CD28(null) T cells and of CMV-specific IFNγ-secreting CD4+ T cells.
OBJECTIVE: Expansion of autoreactive CD4+CD28(null) T cells is associated with extraarticular disease manifestations, including rheumatoid vasculitis, and it has recently been demonstrated that expansion of these T cells is associated with anticytomegalovirus (anti-CMV) seropositivity. This study was undertaken to investigate a possible link between latent CMV infection and rheumatoid arthritis (RA). METHODS: In a retrospective analysis, anti-CMV antibodies and clinical, serologic, and radiologic parameters of joint destruction were examined in 202 RApatients and 272 healthy controls. In addition, frequencies of CD4+CD28(null) T cells; concentrations of the cytokines monocyte chemotactic protein 1 (MCP-1), interferon-α (IFNα), and IFN-inducible protein 10; and anti-CMV-specific T cell responses were analyzed in RApatients. RESULTS: Overall, no significant difference in the frequency of anti-CMV seropositivity between RApatients and healthy controls was observed. Among individuals older than age 55 years, however, anti-CMV IgG antibodies were significantly more frequent in RApatients than controls (65.3% and 54.7%, respectively; P = 0.05). Anti-CMV seropositivity in RApatients was associated with an increased frequency of CD4+CD28(null) T cells and increased serum concentrations of MCP-1. The frequency of anti-CMV-specific CD4+ T cells producing IFNγ was increased in RApatients compared to controls. Most importantly, anti-CMV-seropositive RApatients showed radiographic evidence of more advanced joint destruction and had increased frequencies of joint-related surgical procedures, indicating more severe joint disease. CONCLUSION: Our findings indicate that latent CMV infection aggravates the clinical course of RA and is associated with increased frequencies of CD4+CD28(null) T cells and of CMV-specific IFNγ-secreting CD4+ T cells.
Authors: Laura E Petersen; Jaqueline B Schuch; Lucas A de Azeredo; Talita S A Baptista; Julia G Motta; Aline D do Prado; Moisés Evandro Bauer Journal: Clin Rheumatol Date: 2019-06-11 Impact factor: 2.980
Authors: Ceri A Fielding; Rebecca Aicheler; Richard J Stanton; Eddie C Y Wang; Song Han; Sepehr Seirafian; James Davies; Brian P McSharry; Michael P Weekes; P Robin Antrobus; Virginie Prod'homme; Fabien P Blanchet; Daniel Sugrue; Simone Cuff; Dawn Roberts; Andrew J Davison; Paul J Lehner; Gavin W G Wilkinson; Peter Tomasec Journal: PLoS Pathog Date: 2014-05-01 Impact factor: 6.823
Authors: John M Davis; Keith L Knutson; Michael A Strausbauch; Abigail B Green; Cynthia S Crowson; Terry M Therneau; Eric L Matteson; Sherine E Gabriel Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156
Authors: Natalia Sherina; Hulda S Hreggvidsdottir; Camilla Bengtsson; Monika Hansson; Lena Israelsson; Lars Alfredsson; Karin Lundberg Journal: Arthritis Res Ther Date: 2017-09-30 Impact factor: 5.156